Journal: Cell Reports Medicine
Article Title: Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation
doi: 10.1016/j.xcrm.2024.101711
Figure Lengend Snippet:
Article Snippet: Sections were incubated with primary antibodies: CK19 (ab52625, Abcam, 1:200), Ki67 (ab15580, Abcam, 1:100), Col1 (1310-01, SouthernBiotech, 1:200), αSMA (M0851, DAKO, 1:100), CD4 (ab183685, Abcam, 1; 100), CD8 (85336S, Cell Signaling Technology, 1:100), CD206(AF2535, R&D systems, 1:100), Arginase 1 (ab91279, Abcam, 1:100), CD45 (70257, Cell Signaling Technology, 1:100), p63 (ab124762, Abcam, 1:100), P-ERK (9101S, Cell Signaling Technology, 1:100), CK5 (71536T, Cell Signaling Technology, 1:100), CK8 (MABT329, Sigma, 1:100), Cadherin1 (3195, Cell Signaling Technology, 1; 100), Vimentin (5741, Cell Signaling Technology, 1:100), ZEB1 (NBP1-05987, Novus Biologicals, 1:100) followed by biotinylated secondary antibodies, and streptavidin HRP (Biocare Medical).
Techniques: Virus, Recombinant, Protease Inhibitor, Reverse Transcription, SYBR Green Assay, CCK-8 Assay, Plasmid Preparation, Staining, Bicinchoninic Acid Protein Assay, Sample Prep, Gene Expression, Software